- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: DMT1.
Displaying page 1 of 1.
EudraCT Number: 2016-004772-21 | Sponsor Protocol Number: Dual_Hydrocortisone_gluc_variabilit | Start Date*: 2018-02-22 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Dual-release hydrocortisone compared to immediate-release glucocorticoid replacement therapy in terms of glucose control, insulin sensitivity and glucose variability in patients with adrenal insuff... | |||||||||||||
Medical condition: adrenal insufficienty | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021259-22 | Sponsor Protocol Number: TRX4_DM_008_WW_10 | Start Date*: 2010-12-15 | |||||||||||
Sponsor Name:TolerX, Inc. | |||||||||||||
Full Title: DEFEND-1 Long Term Follow Up: Durable-Response Therapy Evaluation for Early or New Onset Type 1 Diabetes Extension Study | |||||||||||||
Medical condition: Otelixizumab iis being developed for the treatment of patients with autoimmune T1DM with residual beta cell function (RBCF), for the purpose of preserving RBCF in this patient population. Currently... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006550-96 | Sponsor Protocol Number: TN-07 | Start Date*: 2007-03-23 | |||||||||||
Sponsor Name:NIDDK TYPE 1 DIABETES TRIALNET | |||||||||||||
Full Title: Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus | |||||||||||||
Medical condition: prevention of type 1 diabetes mellitus in subjects at risk for T1DM | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) FI (Completed) DE (Completed) GB (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018775-17 | Sponsor Protocol Number: TRX4_DM_019_EU_10 | Start Date*: 2010-07-02 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes | |||||||||||||
Medical condition: Type 1 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Prematurely Ended) FI (Completed) GB (Completed) ES (Completed) IT (Completed) DK (Completed) BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
